Varenicline for smoking cessation: Nausea severity and variation in nicotinic receptor genes

Pharmacogenomics Journal

Volumn 12, Issue 4, 2012, Pages 349-358

  Swan, G E ^a   Javitz, H S ^a   Jack, L M ^a   Wessel, J ^a,b   Michel, M ^a   Hinds, D A ^c,d   Stokowksi, R P ^c,e   Mcclure, J B ^f   Catz, S L ^f   Richards, J ^f   Zbikowski, S M ^g   Deprey, M ^g   Mcafee, T ^g,h   Conti, D V ⁱ   Bergen, A W ^a  

^a SRI INTERNATIONAL   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Perlegen Sciences Inc   (United States)

^d 23 and Me ^*  (United States)

^e Tandem Diagnostics   (United States)

^f GROUP HEALTH RESEARCH INSTITUTE   (United States)

^g Free and Clear   (United States)

^h CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

ⁱ UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

adherence; nausea; smoking cessation; varenicline

Indexed keywords

VARENICLINE;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; ADULT; AGE; ARTICLE; CHRNB2 GENE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; DNA SEQUENCE; FEMALE; GENDER; GENE; GENE FREQUENCY; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; INTRON; MAJOR CLINICAL STUDY; MALE; NAUSEA; NICOTINIC RECEPTOR GENE; OUTCOME ASSESSMENT; PHARMACOGENETICS; PRIORITY JOURNAL; SMOKING CESSATION; TOBACCO DEPENDENCE;

BENZAZEPINES; FEMALE; HUMANS; MALE; MIDDLE AGED; NAUSEA; NICOTINIC AGONISTS; QUINOXALINES; RECEPTORS, NICOTINIC; SMOKING CESSATION;

EID: 84864360423     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2011.19     Document Type: Article

References (51)

1. Coe JW, Brooks PR, Vetelino MG, Wirtz MC, Arnold EP, Huang J et al. Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation. J Med Chem 2005; 48: 3474-3477. (Pubitemid 40664098)
2. Rollema H, Chambers LK, Coe JW, Glowa J, Hurst RS, Lebel LA et al. Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid. Neuropharmacology 2007; 52: 985-994. (Pubitemid 46227486)
3. Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 2008. Issue No. 3. Article No. CD006103.
4. Mihalak KB, Carroll FI, Luetje CW. Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors. Mol Pharmacol 2006; 70: 801-805. (Pubitemid 44268437)
5. Cahill K, Stead L, Lancaster T. A preliminary benefit-risk assessment of varenicline in smoking cessation. Drug Saf 2009; 32: 119-135.
6. Kasliwal R, Wilton LV, Shakir SA. Safety and drug utilization profile of varenicline as used in general practice in England: interim results from a prescription-event monitoring study. Drug Saf 2009; 32: 499-507.
7. Rigotti NA, Pipe AL, Benowitz NL, Arteaga C, Garza D, Tonstad S. Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial. Circulation 2010; 121: 221-229.
8. Mandl P, Kiss JP. Role of presynaptic nicotinic acetylcholine receptors in the regulation of gastrointestinal motility. Brain Res Bull 2007; 72: 194-200. (Pubitemid 46602756)
9. Sanger GJ, Andrews PL. Treatment of nausea and vomiting: gaps in our knowledge. Auton Neurosci 2006; 129: 3-16. (Pubitemid 44472635)
10. Ehringer MA, Clegg HV, Collins AC, Corley RP, Crowley T, Hewitt JK et al. Association of the neuronal nicotinic receptor beta2 subunit gene (CHRNB2) with subjective responses to alcohol and nicotine. Am J Med Genet B Neuropsychiatr Genet 2007; 144B: 596-604. (Pubitemid 47077142)
11. Conti DV, Lee W, Li D, Liu J, Van Den Berg D, Thomas PD et al. Nicotinic acetylcholine receptor beta2 subunit gene implicated in a systemsbased candidate gene study of smoking cessation. Hum Mol Genet 2008; 17: 2834-2848.
12. Halperin AC, McAfee TA, Jack LM, Catz SL, McClure JB, Deprey TM et al. Impact of symptoms experienced by varenicline users on tobacco treatment in a real world setting. J Subst Abuse Treat 2009; 36: 428-434.
13. Wessel J, McDonald SM, Hinds DA, Stokowski RP, Javitz HS, Kennemer M et al. Resequencing of nicotinic acetylcholine receptor genes and association of common and rare variants with the Fagerström test for nicotine dependence. Neuropsychopharmacology 2010; 35: 2392-2402.
14. McClure JB, Swan GE, Catz SL, Jack L, Javitz H, McAfee T et al. Smoking outcome by psychiatric history after behavioral and varenicline treatment. J Subst Abuse Treat 2010; 38: 394-402.
15. McClure JB, Swan GE, Jack L, Catz SL, Zbikowski SM, McAfee TA et al. Mood, side-effects and smoking outcomes among persons with and without probable lifetime depression taking varenicline. J Gen Intern Med 2009; 24: 563-569.
16. Swan GE, McClure JB, Jack LM, Zbikowski SM, Javitz HS, Catz SL et al. Behavioral counseling and varenicline treatment for smoking cessation. Am J Prev Med 2010; 38: 482-490.
17. Fiore MC, Jaén CR, Baker TB, Bailey WC, Benowitz NL, Curry SJ et al. (2008) Treating tobacco use and dependence: 2008 update. In: Clinical Practice Guideline. US Department of Health and Human Services. Public Health Service: Clincial Practice Guideline: Rockville, MD.
18. Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO. The Fagerström test for nicotine dependence: a revision of the Fagerström Tolerance Questionnaire. Br J Addict 1991; 86: 1119-1127.
19. Nishita DM, Jack LM, McElroy M, McClure JB, Richards J, Swan GE et al. Clinical trial participant characteristics and saliva and DNA metrics. BMC Med Res Methodol 2009; 9: 71.
20. Margulies M, Egholm M, Altman WE, Attiya S, Bader JS, Bemben LA et al. Genome sequencing in microfabricated high-density picolitre reactors. Nature 2005; 437: 376-380. (Pubitemid 41613494)
21. Sanger F, Nicklen S, Coulson AR. DNA sequencing with chainterminating inhibitors. Proc Natl Acad Sci USA 1977; 74: 5463-5467.
22. Conneely KN, Boehnke M. So many correlated tests, so little time! Rapid adjustment of P values for multiple correlated tests. Am J Hum Genet 2007; 81: p1158-1168. (Pubitemid 350211447)
23. Madsen BE, Browning SR. A groupwise association test for rare mutations using a weighted sum statistic. PLoS Genet 2009; 5: e1000384.
24. Kryukov GV, Shpunt A, Stamatoyannopoulos JA, Sunyaev SR. Power of deep, all-exon resequencing for discovery of human trait genes. Proc Natl Acad Sci USA 2009; 106: 3871-3876.
25. Nievergelt CM, Libiger O, Schork NJ. Generalized analysis of molecular variance. PLoS Genet 2007; 3: e51.
26. Schork NJ, Wessel J, Malo N. DNA sequence-based phenotypic association analysis. Adv Genet 2008; 60: 195-217.
27. Wessel J, Schork NJ. Generalized genomic distance-based regression methodology for multilocus association analysis. Am J Hum Genet 2006; 79: 792-806. (Pubitemid 44763395)
28. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21: 263-265. (Pubitemid 40202029)
29. Frazer KA, Ballinger DG, Cox DR, Hinds DA, Stuve LL, Gibbs RA et al. A second generation human haplotype map of over 3.1 million SNPs. Nature 2007; 449: 851-861. (Pubitemid 47598626)
30. Ehringer MA, McQueen MB, Hoft NR, Saccone NL, Stitzel JA, Wang JC et al. Association of CHRN genes with 'dizziness' to tobacco. Am J Med Genet B Neuropsychiatr Genet 2010; 153B: 600-609.
31. Hoft NR, Stitzel JA, Hutchison KE, Ehringer MA. CHRNB2 promoter region: association with subjective effects to nicotine and gene expression differences. Genes Brain Behav 2010; 10: 176-185.
32. Perkins KA, Lerman C, Mercincavage M, Fonte CA, Briski JL. Nicotinic acetylcholine receptor beta2 subunit (CHRNB2) gene and short-term ability to quit smoking in response to nicotine patch. Cancer Epidemiol Biomarkers Prev 2009; 18: 2608-2612.
33. Etter JF, Hoda JC, Perroud N, Munafo M, Buresi C, Duret C et al. Association of genes coding for the alpha-4, alpha-5, beta-2 and beta-3 subunits of nicotinic receptors with cigarette smoking and nicotine dependence. Addict Behav 2009; 34: 772-775.
34. Feng Y, Niu T, Xing H, Xu X, Chen C, Peng S et al. A common haplotype of the nicotine acetylcholine receptor alpha 4 subunit gene is associated with vulnerability to nicotine addiction in men. Am J Hum Genet 2004; 75: 112-121. (Pubitemid 38801907)
35. Li MD, Beuten J, Ma JZ, Payne TJ, Lou XY, Garcia V et al. Ethnic-and gender-specific association of the nicotinic acetylcholine receptor alpha4 subunit gene (CHRNA4) with nicotine dependence. Hum Mol Genet 2005; 14: 1211-1219. (Pubitemid 40613909)
36. Weiss RB, Baker TB, Cannon DS, von Niederhausern A, Dunn DM, Matsunami N et al. A candidate gene approach identifies the CHRNA5-A3-B4 region as a risk factor for age-dependent nicotine addiction. PLoS Genet 2008; 4: e1000125.
37. Bergen AW, Conti DV, Van Den Berg D, LeeW, Liu J, Li D et al. Dopamine genes and nicotine dependence in treatment-seeking and community smokers. Neuropsychopharmacology 2009; 34: 2252-2264.
38. Lueders KK, Hu S, McHugh L, Myakishev MV, Sirota LA, Hamer DH. Genetic and functional analysis of single nucleotide polymorphisms in the beta2-neuronal nicotinic acetylcholine receptor gene (CHRNB2). Nicotine Tob Res 2002; 4: 115-125. (Pubitemid 34521104)
39. Silverman MA, Neale MC, Sullivan PF, Harris-Kerr C, Wormley B, Sadek H et al. Haplotypes of four novel single nucleotide polymorphisms in the nicotinic acetylcholine receptor beta2-subunit (CHRNB2) gene show no association with smoking initiation or nicotine dependence. Am J Med Genet 2000; 96: 646-653.
40. Andrews PL, Horn CC. Signals for nausea and emesis: implications for models of upper gastrointestinal diseases. Auton Neurosci 2006; 125: 100-115.
41. Shoaib M, Gommans J, Morley A, Stolerman IP, Grailhe R, Changeux JP. The role of nicotinic receptor beta-2 subunits in nicotine discrimination and conditioned taste aversion. Neuropharmacology 2002; 42: 530-539. (Pubitemid 34304245)
42. Salminen O, Murphy KL, McIntosh JM, Drago J, Marks MJ, Collins AC et al. Subunit composition and pharmacology of two classes of striatal presynaptic nicotinic acetylcholine receptors mediating dopamine release in mice. Mol Pharmacol 2004; 65: 1526-1535. (Pubitemid 38668310)
43. Stowe RL, Ives NJ, Clarke C, van Hilten J, Ferreira J, Hawker RJ et al. Dopamine agonist therapy in early Parkinson's disease. Cochrane Database Syst Rev 2008. Issue No. 2. Article No. CD006564.
44. Rowbotham MC, Duan WR, Thomas J, Nothaft W, Backonja MM. A randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of ABT-594 in patients with diabetic peripheral neuropathic pain. Pain 2009; 146: 245-252.
45. DiFranza JR, Savageau JA, Fletcher K, Ockene JK, Rigotti NA, McNeill AD et al. Recollections and repercussions of the first inhaled cigarette. Addict Behav 2004; 29: 261-272. (Pubitemid 38083242)
46. Pomerleau CS, Pomerleau OF, Namenek RJ, Marks JL. Initial exposure to nicotine in college-age women smokers and never-smokers: a replication and extension. J Addict Dis 1999; 18: 13-19. (Pubitemid 29479605)
47. Pomerleau OF, Pomerleau CS, Namenek RJ. Early experiences with tobacco among women smokers, ex-smokers, and never-smokers. Addiction 1998; 93: 595-599. (Pubitemid 28188079)
48. Toll BA, McKee SA, Martin DJ, Jatlow P, O'Malley SS. Factor structure and validity of the Medication Adherence Questionnaire (MAQ) with cigarette smokers trying to quit. Nicotine Tob Res 2007; 9: 597-605. (Pubitemid 46672438)
49. Hughes Jr. Effects of abstinence from tobacco: valid symptoms and time course. Nicotine Tob Res 2007; 9: 315-327. (Pubitemid 46404264)
50. Mills EJ, Wu P, Lockhart I, Wilson K, Ebbert JO. Adverse events associated with nicotine replacement therapy (NRT) for smoking cessation. A systematic review and meta-analysis of one hundred and twenty studies involving 177,390 individuals. Tob Induc Dis 2010; 8: 8.
51. Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev 2007. Issue No. 1. Article No. CD000031.